Investigation of potential therapeutic targets for glioblastoma using a mouse ipsc-derived model of glioblastoma initiating cells
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Poster
- By: ZHANG, Yi (Monash Institute of Pharmaceutical Science, Drug Discovery Biology, Parkville, Australia)
- Co-author(s): Haynes, John (Monash Institute of Pharmaceutical Science, Parkville, Australia)
Mantamadiotis, Theo (The University of Melbourne, Parkville, Australia)
Pouton, Colin (Monash Institute of Pharmaceutical Science, Parkville, Australia)
Glioblastoma (GB) is the most common and aggressive malignant brain tumor with an invariably poor prognosis. GB is virtually incurable due to high drug resistance and relapse after chemotherapy, which highlights the urgent need for novel GB therapeutics. Recent studies suggest that relapse is due to gliobalstoma initiating cells.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.